Freed
We're Hiring!
Freed Company Growth, Stability & Outlook
What People Are Saying About Freed
-
Strong Revenue Growth: Analyst estimates and company milestones describe rapid ARR increases and rising clinician adoption through 2025. Reports also point to continued product shipping into 2026, consistent with an expanding commercial footprint.
-
Investor Backing & Capital Strength: Trade press reported a sizable Series A in March 2025 led by top-tier investors, signaling access to capital for scaling. Coverage frames the raise as intended to accelerate product and go-to-market execution.
-
Product Line Growth: Company communications and press note rollouts like EHR push, specialty templates, and adjacent tools (e.g., an AI receptionist), indicating widening solution scope. Ongoing releases across 2025–2026 suggest active development beyond the core scribe.
